High-throughput screen using a single-cell tyrosine phosphatase assay reveals biologically active inhibitors of tyrosine phosphatase CD45

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 35, 2012, Pages 13972-13977

  Stanford, Stephanie M ^a,b   Panchal, Rekha G ^c   Walker, Logan M ^a   Wu, Dennis J ^a   Falk, Matthew D ^a   Mitra, Sayantan ^b   Damle, Sagar S ^d   Ruble, David ^b   Kaltcheva, Teodora ^b,e   Zhang, Sheng ^f   Zhang, Zhong Yin ^f   Bavari, Sina ^c   Barrios, Amy M ^b,e   Bottini, Nunzio ^a,b  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Peptide substrate; Single cell assay

Indexed keywords

CD45 ANTIGEN; PHOSPHORYLATED COUMARYL AMINO PROPIONIC ACID; PHOSPHOTYROSINE; PROPIONIC ACID; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ARTICLE; BIOASSAY; CELL MEMBRANE PERMEABILITY; HIGH THROUGHPUT SCREENING; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; SENSITIVITY ANALYSIS;

ANTHRAX; ANTIGENS, CD45; BACILLUS ANTHRACIS; CYTOPROTECTION; DRUG DISCOVERY; ENZYME ACTIVATION; ENZYME INHIBITORS; FLOW CYTOMETRY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; JURKAT CELLS; OLIGOPEPTIDES; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASES; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY; T-LYMPHOCYTES;

EID: 84865538949     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1205028109     Document Type: Article

References (28)

1. Tautz L, Pellecchia M, Mustelin T (2006) Targeting the PTPome in human disease. Expert Opin Ther Targets 10:157-177. (Pubitemid 43263273)
2. Hermiston ML, Xu Z, Weiss A (2003) CD45: A critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 21:107-137. (Pubitemid 37174528)
3. Barr AJ (2010) Protein tyrosine phosphatases as drug targets: Strategies and challenges of inhibitor development. Future Med Chem 2:1563-1576.
4. Chan G, Kalaitzidis D, Neel BG (2008) The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev 27:179-192.
5. Blaskovich MA (2009) Drug discovery and protein tyrosine phosphatases. Curr Med Chem 16:2095-2176.
6. Meng TC, Hsu SF, Tonks NK (2005) Development of a modified in-gel assay to identify protein tyrosine phosphatases that are oxidized and inactivated in vivo. Methods 35: 28-36.
7. Persson C, Kappert K, Engström U, Ostman A, Sjöblom T (2005) An antibody-based method for monitoring in vivo oxidation of protein tyrosine phosphatases. Methods 35:37-43. (Pubitemid 39647577)
8. Karisch R, et al. (2011) Global proteomic assessment of the classical protein-tyrosine phosphatome and "Redoxome". Cell 146:826-840.
9. Zikherman J, et al. (2010) CD45-Csk phosphatase-kinase titration uncouples basal and inducible T cell receptor signaling during thymic development. Immunity 32:342-354.
10. Panchal RG, et al. (2009) Reduced expression of CD45 protein-tyrosine phosphatase provides protection against anthrax pathogenesis. J Biol Chem 284:12874-12885.
11. Mitra S, Barrios AM (2005) Highly sensitive peptide-based probes for protein tyrosine phosphatase activity utilizing a fluorogenic mimic of phosphotyrosine. Bioorg Med Chem Lett 15:5142-5145. (Pubitemid 41463635)
12. Karver MR, Krishnamurthy D, Kulkarni RA, Bottini N, Barrios AM (2009) Identifying potent, selective protein tyrosine phosphatase inhibitors from a library of Au(I) complexes. J Med Chem 52:6912-6918.
13. Mitra S, Barrios AM (2008) Identifying selective protein tyrosine phosphatase substrates and inhibitors from a fluorogenic, combinatorial peptide library. ChemBioChem 9:1216-1219.
14. Mustelin T, Taskén K (2003) Positive and negative regulation of T-cell activation through kinases and phosphatases. Biochem J 371:15-27.
15. Yu X, et al. (2007) Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases. Proc Natl Acad Sci USA 104:19767-19772.
16. Patel LN, Zaro JL, Shen WC (2007) Cell penetrating peptides: Intracellular pathways and pharmaceutical perspectives. Pharm Res 24:1977-1992. (Pubitemid 47493563)
17. Pham W, Kircher MF, Weissleder R, Tung CH (2004) Enhancing membrane permeability by fatty acylation of oligoarginine peptides. ChemBioChem 5:1148-1151. (Pubitemid 39257039)
18. Barr AJ, et al. (2009) Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 136:352-363.
19. Nam HJ, Poy F, Saito H, Frederick CA (2005) Structural basis for the function and regulation of the receptor protein tyrosine phosphatase CD45. J Exp Med 201:441-452. (Pubitemid 40229418)
20. Orrú V, et al.; Italian Collaborative Group (2009) A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Hum Mol Genet 18:569-579.
21. Sun H, Tan LP, Gao L, Yao SQ (2009) High-throughput screening of catalytically inactive mutants of protein tyrosine phosphatases (PTPs) in a phosphopeptide microarray. Chem Commun (Camb) (6):677-679.
22. Koretzky GA, Picus J, Schultz T, Weiss A (1991) Tyrosine phosphatase CD45 is required for T-cell antigen receptor and CD2-mediated activation of a protein tyrosine kinase and interleukin 2 production. Proc Natl Acad Sci USA 88:2037-2041. (Pubitemid 21916348)
23. Zhang S, et al. (2009) Acquisition of a potent and selective TC-PTP inhibitor via a stepwise fluorophore-tagged combinatorial synthesis and screening strategy. J Am Chem Soc 131:13072-13079.
24. Stanford SM, et al. (2011) Discovery of a novel series of inhibitors of lymphoid tyrosine phosphatase with activity in human T cells. J Med Chem 54:1640- 1654.
25. Gomer CJ, et al. (1996) Photodynamic therapy-mediated oxidative stress can induce expression of heat shock proteins. Cancer Res 56:2355-2360. (Pubitemid 26155168)
26. Barr AJ, Knapp S (2006) MAPK-specific tyrosine phosphatases: New targets for drug discovery? Trends Pharmacol Sci 27:525-530. (Pubitemid 44374759)
27. Lee K, Burke TR, Jr. (2003) CD45 protein-tyrosine phosphatase inhibitor development. Curr Top Med Chem 3:797-807.
28. Edwards BS, et al. (2009) High-content screening: Flow cytometry analysis. Methods Mol Biol 486:151-165.